3q-26 Test

Personalized Patient Care

The Genetic Pap

West Coast Pathology Laboratories is one of the leading providers of anatomic pathology, cytology and molecular diagnostics. To perform the 3Q-26 FHACT test, which detects genomic alterations associated with progression of cervical lesions, we use a digital microscopy system that provides fully-automated FISH scoring and preliminary analysis. The combination of automation and our scientifically/medical expertise provide our clients with highly objective, accurate results.

WHAT IS 3Q-26 GAIN?

  • 3Q-26 Gain is a mutation caused by High Risk HPV viruses that is associated with patients who will progress to HSIL/CIS
  • The absence of this HPV induced mutation identifies those who WILL NOT progress to HSIL/CIS (99% NPV)
  • This test is an efficient biomarker for the patient’s response to HPV   

WHO BENEFITS FROM THE TEST?

 Major Benefit accrues to those who are:

  • HR HPV Positive with Negative PAP
  • HR HPV Positive with ASCUS
  • HR HPV positive with LSIL
  • Post colposcopy -recurrent HPV or abnormal cytology result

WHY WILL THE 3Q-26 GAIN RESULTS CHANGE MY COURSE OF TREATMENT?

  • HPV status does NOT differentiate those who may progress to a high grade dysplasia (HSIL) from those that will regress. The 3Q-26 gain will identify patients who will REGRESS (negative) as opposed to those who will PROGRESS (positive) to HSIL.

85% of individuals sent to colposcopy will regress. They are 3Q-26 “Negative.” Knowing this information will help eliminate unnecessary procedures and frequent repeat pap tests for the patient.

The other 15% of patients that are 3Q-26 positive will progress. This allows you better to focus on these patients at higher risk and personalize their care.                                                                                                    

HPV DETERMINES RISK

3Q-26 GAIN DETECTS DISEASE